Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Long-term follow-up of people who received EDIT-301 for sickle cell or thalassemia

Follows people with sickle cell disease or beta-thalassemia who received EDIT-301 over time.

Plain-language title generated from the registry record
Registry title: A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

Key facts

Where
Atlanta, Aurora, Charleston, Charlotte, Cleveland, Columbus, Dallas, Fort Worth, Minneapolis, Nashville, New Haven, New York, Oakland, Philadelphia, and St. Petersburg, United StatesSee the 16 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 50 years old?

Source: NCT06363760, who can take part

Where in United States

  • Children's Healthcare of AtlantaAtlanta, United StatesNo longer taking part
  • Children's Hospital ColoradoAurora, United StatesNo longer taking part
  • Medical University of South CarolinaCharleston, United StatesNo longer taking part
  • Atrium HealthCharlotte, United StatesNo longer taking part
  • Cleveland ClinicCleveland, United StatesNo longer taking part
  • Nationwide Children's HospitalColumbus, United StatesNo longer taking part
  • Texas Oncology - Baylor Charles A. Sammons Cancer CenterDallas, United StatesNo longer taking part
  • Cook Children'sFort Worth, United StatesNo longer taking part
  • University of MinnesotaMinneapolis, United StatesNo longer taking part
  • Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood CancersNashville, United StatesNo longer taking part
  • Smilow Cancer HospitalNew Haven, United StatesNo longer taking part
  • Columbia University Medical CenterNew York, United StatesNo longer taking part
  • Columbia University Medical Center - Department of PediatricsNew York, United StatesNo longer taking part
  • UCSF Benioff Children s HospitalOakland, United StatesNo longer taking part
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesNo longer taking part
  • Johns Hopkins All Children's HospitalSt. Petersburg, United StatesNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Editas Medicine, Inc.
Trial code
NCT06363760
Record updated
2 April 2025
Original description
The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.Read full original descriptionShow less

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.

Inclusion: Participant must have received an EDIT-301 infusion as part of a clinical study; Participant or legal representative/guardian (if applicable) must sign and date the informed consent form (ICF) or assent, if applicable for this long-term follow-up study.

Exclusion: Participant is still actively enrolled in an EDIT-301 treatment study and has not yet met eligibility for long term follow-up in this study.

ClinicalTrials.gov NCT06363760